Anaptysbio (ANAB) Profit After Tax (2016 - 2026)
Anaptysbio posted quarterly Profit After Tax of -$52.9 million for Q1 2026, down 34.47% year-on-year from -$80.7 million in Q1 2025, and down 206.59% on a QoQ basis from $49.6 million in Q4 2025.
Anaptysbio (ANAB) has 11 years of Profit After Tax data on file, last reported at -$52.9 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax fell 34.47% year-over-year to -$52.9 million; the trailing twelve-month figure through Mar 2026 stood at -$26.8 million (up 80.95% YoY), and the FY2025 full-year result was -$13.2 million, up 90.89% from the prior year.
- Profit After Tax for Q1 2026 stood at -$52.9 million, down from $49.6 million in the prior quarter.
- Across five years, Profit After Tax topped out at $49.6 million in Q4 2025 and bottomed at -$52.9 million in Q1 2026.
- The 5-year median for Profit After Tax is -$37.3 million (2023), against an average of -$29.6 million.
- The widest annual swing landed in 2022, when Profit After Tax slumped 7488.34%; it then jumped 327.75% in 2025.
- A 5-year view of Profit After Tax shows it stood at -$26.4 million in 2022, then sank by 59.81% to -$42.2 million in 2023, then jumped by 48.39% to -$21.8 million in 2024, then surged by 327.75% to $49.6 million in 2025, then sank by 206.59% to -$52.9 million in 2026.
- The last three Profit After Tax figures came in at -$52.9 million (Q1 2026), $49.6 million (Q4 2025), and $15.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Anaptysbio | 1.60 Bn | 1.31 Bn | - | -52.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.88 Mn |
| Dec 31, 2025 | 49.61 Mn |
| Sep 30, 2025 | 15.11 Mn |
| Jun 30, 2025 | -38.63 Mn |
| Mar 31, 2025 | -39.33 Mn |
| Dec 31, 2024 | -21.78 Mn |
| Sep 30, 2024 | -32.85 Mn |
| Jun 30, 2024 | -46.66 Mn |
| Mar 31, 2024 | -43.94 Mn |
| Dec 31, 2023 | -42.21 Mn |
| Sep 30, 2023 | -37.31 Mn |
| Jun 30, 2023 | -39.85 Mn |
| Mar 31, 2023 | -44.26 Mn |
| Dec 31, 2022 | -26.41 Mn |
| Sep 30, 2022 | -33.50 Mn |
| Jun 30, 2022 | -32.55 Mn |
| Mar 31, 2022 | -36.26 Mn |
| Dec 31, 2021 | -32.54 Mn |
| Sep 30, 2021 | -6.67 Mn |
| Jun 30, 2021 | -429,000.00 |
| Mar 31, 2021 | -18.16 Mn |
| Dec 31, 2020 | 33.65 Mn |
| Sep 30, 2020 | -23.77 Mn |
| Jun 30, 2020 | -21.55 Mn |
| Mar 31, 2020 | -8.26 Mn |
| Dec 31, 2019 | -20.26 Mn |
| Sep 30, 2019 | -31.03 Mn |
| Jun 30, 2019 | -23.96 Mn |
| Mar 31, 2019 | -22.08 Mn |
| Dec 31, 2018 | -16.99 Mn |
| Sep 30, 2018 | -15.96 Mn |
| Jun 30, 2018 | -13.62 Mn |
| Mar 31, 2018 | -15.09 Mn |
| Dec 31, 2017 | -6.86 Mn |
| Sep 30, 2017 | -9.09 Mn |
| Jun 30, 2017 | -2.68 Mn |
| Mar 31, 2017 | -11.44 Mn |
| Dec 31, 2016 | -4.58 Mn |
| Sep 30, 2016 | -1.12 Mn |
| Jun 30, 2016 | 2.32 Mn |
| Mar 31, 2016 | -888,000.00 |